Predicting lung exposure of intramuscular niclosamide as an antiviral agent: Power‐law based pharmac...
Predicting lung exposure of intramuscular niclosamide as an antiviral agent: Power‐law based pharmacokinetic modeling
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Niclosamide, a potent anthelmintic agent, has emerged as a candidate against COVID‐19 in recent studies. Its formulation has been investigated extensively to address challenges related to systemic exposure. In this study, niclosamide was formulated as a long‐acting intramuscular injection to achieve systemic exposure in the lungs for combating the...
Alternative Titles
Full title
Predicting lung exposure of intramuscular niclosamide as an antiviral agent: Power‐law based pharmacokinetic modeling
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_8d490a5b2b1041f6905779031fdb9cae
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8d490a5b2b1041f6905779031fdb9cae
Other Identifiers
ISSN
1752-8054
E-ISSN
1752-8062
DOI
10.1111/cts.13833
